An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.